dan 2163 has been researched along with fluphenazine in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Boyer, P; Lecrubier, Y; Puech, AJ | 1 |
Anderer, P; Földes, P; Grünberger, J; Küfferle, B; Saletu, B; Topitz, A | 1 |
El Ela, AA; Härtter, S; Hiemke, C; Langguth, P; Schmitt, U; Spahn-Langguth, H | 1 |
Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A | 1 |
Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S | 1 |
Osman, E; Yıldız, M | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for dan 2163 and fluphenazine
Article | Year |
---|---|
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fluphenazine; Humans; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Treatment Outcome | 2016 |
2 trial(s) available for dan 2163 and fluphenazine
Article | Year |
---|---|
Treatment of positive and negative symptoms: pharmacologic approaches.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sulpiride | 1990 |
Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
Topics: Adult; Amisulpride; Antipsychotic Agents; Arousal; Attention; Brain Mapping; Cerebral Cortex; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Fluphenazine; Humans; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Psychometrics; Schizophrenia; Schizophrenic Psychology; Signal Processing, Computer-Assisted; Sulpiride | 1994 |
4 other study(ies) available for dan 2163 and fluphenazine
Article | Year |
---|---|
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
Topics: Amisulpride; Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Brain; Caco-2 Cells; Cyclosporine; Drug Interactions; Fluphenazine; Humans; Immunosuppressive Agents; Male; Rats; Substrate Specificity; Sulpiride; Tissue Distribution | 2004 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzothiazepines; Emotions; Fluphenazine; Haloperidol; Humans; Memory; Middle Aged; Olanzapine; Perazine; Perphenazine; Quetiapine Fumarate; Recognition, Psychology; Risperidone; Schizophrenia; Sulpiride | 2012 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |